Elanco director buys 5,000 company shares

Elanco Animal Health Inc director Michael J. Harrington purchased 5,000 shares of common stock on 2026-08-12 in an open market or private transaction at a price of $21.82 per share.

Rhea-AI Filing Summary

Elanco Animal Health Inc director Michael J. Harrington purchased 5,000 shares of common stock on 2026-08-12 in an open market or private transaction at a price of $21.82 per share. Following this transaction, his directly held position increased to 131,451 shares of Elanco common stock.

Insider Trade Summary

Net Buyer: 5,000 shares

Net Buy 1 txn

Insider Harrington Michael J

Role Director

Bought 5,000 shs ($109K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	5,000	$21.82	$109K

Holdings After Transaction: Common Stock — 131,451 shares (Direct)

Key Figures

Shares purchased: 5,000 shares Purchase price: $21.82 per share Holdings after transaction: 131,451 shares

3 metrics

Shares purchased 5,000 shares Common Stock purchased on 2026-08-12

Purchase price $21.82 per share Price for Common Stock purchase on 2026-08-12

Holdings after transaction 131,451 shares Total Common Stock directly owned by director after purchase

Key Terms

purchase in open market or private transaction, Common Stock, non-derivative

3 terms

purchase in open market or private transaction regulatory

"Transaction code description is purchase in open market or private transaction"

Common Stock financial

"Security title is Common Stock in the reported transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

non-derivative financial

"Transaction type is non-derivative for the Common Stock purchase"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Elanco Animal Health (ELAN) report?

Elanco Animal Health reported that director Michael J. Harrington purchased 5,000 shares of common stock. The transaction occurred on 2026-08-12 as a purchase in open market or private transaction, according to the Form 4 disclosure.

At what price did the Elanco (ELAN) director buy shares?

Director Michael J. Harrington bought 5,000 Elanco shares at $21.82 per share. The filing identifies the transaction as a purchase in open market or private transaction, with the price reported on a per-share basis.

How many Elanco (ELAN) shares does the director hold after this trade?

After the reported transaction, director Michael J. Harrington holds 131,451 shares of Elanco common stock directly. This reflects the addition of 5,000 shares purchased on 2026-08-12 in an open market or private transaction.

Was the Elanco (ELAN) insider trade under a Rule 10b5-1 plan?

The transaction was not reported under a Rule 10b5-1 trading plan. The filing’s related checkbox is not marked as affirmed, and no footnote indicates that the purchase was made pursuant to a pre-arranged trading plan.

What type of security did the Elanco (ELAN) director acquire?

The director acquired Common Stock of Elanco Animal Health Inc. The Form 4 specifies a non-derivative transaction involving 5,000 shares of common stock, purchased at $21.82 per share on 2026-08-12.

Is the Elanco (ELAN) insider transaction a buy or a sell?

The reported insider transaction is a buy. Director Michael J. Harrington executed a purchase of 5,000 Elanco common shares on 2026-08-12, categorized as a purchase in open market or private transaction in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/13/2026 - 04:29 PM Accepted by SEC EDGAR 08/13/2026 - 04:28 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Harrington Michael J

(Last) (First) (Middle)

C/O ELANCO ANIMAL HEALTH INCORPORATED

450 ELANCO CIRCLE

(Street)

INDIANAPOLIS INDIANA 46221

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2026		P		5,000	A	$21.82	131,451	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Amy C. Seidel, as Attorney-in-Fact for Michael J. Harrington	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)